Decreased CD161 activating and increased CD158a inhibitory receptor expression on NK cells underlies impaired NK cell cytotoxicity in patients with multiple myeloma

Journal of Clinical Pathology

Volumn 69, Issue 11, 2016, Pages 1009-1016

  Konjević, Gordana ^a,b   Vuletić, Ana ^a   Mirjačić Martinović, Katarina ^a   Colović, Nataša ^b,c   Čolović, Milica ^b   Jurišić, Vladimir ^d  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c CLINICAL CENTER OF SERBIA   (Serbia)

^d University of Kragujevac Medical Faculty   (Serbia)

Author keywords

CYTOKINES; CYTOMETRY; DIAGNOSIS; ELISA; MYELOMA

Indexed keywords

CD16 ANTIGEN; CD161 ANTIGEN; CD3 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL3; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; NATURAL KILLER CELL RECEPTOR; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; CANCER IMMUNOLOGY; CANCER PATIENT; CELL LEVEL; CHROMIUM RELEASE ASSAY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; FEMALE; FLOW CYTOMETRY; GAMMA DELTA T LYMPHOCYTE; HUMAN; IN VITRO STUDY; LYMPHOCYTE FUNCTION; MALE; MULTIPLE MYELOMA; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84964621979     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2016-203614     Document Type: Article

References (56)

1. Dosani T, Carlsten M, Maric I, et al. The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies. Blood Cancer J 2015; 5: e321
2. Biron CA, Nguyen KB, Pien GC, et al. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Ann Rev Immunol 1999; 17: 189-220
3. Cooper MA, Fehniger TA, Caligiuri M.A. The biology of human natural killer-cell subsets. Trends Immunol 2001; 22: 633-40
4. Nagler A, Lanier LL, Cwirla S, et al. Comparative studies of human FcRIII-positive and negative natural killer cells. J Immunol 1989; 143: 3183-91
5. Lanier LL, Le AM, Civin CI, et al. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol 1986; 136: 4480-6
6. Cooper MA, Fehniger TA, Turner SC, et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset. Blood 2001; 97: 3146-51
7. KonjevićG, VuletićA, Mirjaç.ićMartinovićK. Natural killer cell receptors: alterations and therapeutic targeting in malignancies. Immunol Res 2016; 64: 25-35
8. Benson DM Jr, Caligiuri M.A. Killer immunoglobulin-like receptors and tumor immunity. Cancer Immunol Res 2014; 2: 99-104
9. Jaeger BN, Vivier E. When NK cells overcome their lack of education. J Clin Invest 2012; 122: 3053-6
10. Lanier LL. NK cell receptors. Annu Rev Immunol 1986; 16: 359-93
11. Farag SS, Caligiuri M.A. Human natural killer cell development and biology. Blood Rev 2006; 20: 123-37
12. Stojanovic A, Correia MP, Cerwenka A. Shaping of NK cell responses by the tumor microenvironment. Cancer Microenviron 2013; 6: 135-46
13. Gibson SE, Swerdlow SH, Felgar RE. Natural killer cell subsets and natural killerlike T-cell populations in benign and neoplastic B-cell proliferations vary based on clinicopathologic features. Hum Pathol 2011; 42: 679-87
14. Bonneville M, O'Brien RL, Born WK. Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity. Nat Rev Immunol 2010; 10: 467-78
15. KonjevićG, MirjacićMartinovićK, VuletićA, et al. Distribution of several activating and inhibitory receptors on CD3-CD16+ NK cells and their correlation with NK cell function in healthy individuals. J Membr Biol 2009; 230: 113-23
16. Brown RL, Ortaldo JR, Griffith RL, et al. The proliferation and function of human mononuclear leukocytes and natural killer cells in serum-free medium. J Immunol Methods 1985; 81: 207-14
17. Frohn C, Höppner M, Schlenke P, et al. Anti-myeloma activity of natural killer lymphocytes. Br J Haematol 2002; 119: 660-4
18. Spanoudakis E, Hu M, Naresh K, et al. Regulation of multiple myeloma survival and progression by CD1d. Blood 2009; 113: 2498-507
19. Van den Hove LE, Meeus P, Derom A, et al. Lymphocyte profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: flow-cytometric characterization and analysis in a two-dimensional correlation biplot. Ann Hematol 1998; 76: 249-56
20. King MA, Radicchi-Mastroianni M.A. Natural killer cells and CD56+ T cells in the blood of multiple myeloma patients: analysis by 4-colour flow cytometry. Cytometry 1996; 26: 121-4
21. Schütt P, Brandhorst D, Stellberg W, et al. Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections. Leuk Lymphoma 2006; 47: 1570-82
22. Nur H, Fostier K, Aspeslagh S, et al. Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model. PLoS One 2013; 8(5): e65075
23. Liao W, Lin JX, Leonard WJ. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 2013; 38: 13-25
24. KonjevićG, JurisićV, Banićevic B, et al. The difference in NK-cell activity between patients with non-Hodgkin's lymphomas and Hodgkin's disease. Br J Haematol 1999; 104: 144-51
25. Costello RT, Fauriat C, Sivori S, et al. NK cells: innate immunity against hematological malignancies?. Trends Immunol 2004; 25: 328-33
26. Kiladjian JJ, Bourgeois E, Lobe I, et al. Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes. Leukemia 2006; 20: 463-70
27. Seidel MG, Freissmuth M, Pehamberger H, et al. Stimulation of natural killer activity in peripheral blood lymphocytes of healthy donors and melanoma patients in vitro: synergism between interleukin (IL)-12 and IL-15 or IL-12 and IL-2. Naunyn Schmiedebergs Arch Pharmacol 1998; 358: 382-9
28. Sibbitt WL Jr, Bankhurst AD, Jumonville AJ, et al. Defects in natural killer cell activity and interferon response in human lung carcinoma and malignant melanoma. Cancer Res 1984; 44: 852-6
29. KonjevićG, MirjacićMartinovićK, VuletićA, et al. Low expression of CD161 and NKG2D activating NK receptor is associated with impaired NK cell cytotoxicity in metastatic melanoma patients. Clin Exp Metastasis 2007; 24: 1-11
30. KonjevićG, JurisićV, SpuzićI. Association of NK cell dysfunction with changes in LDH characteristics of peripheral blood lymphocytes (PBL) in breast cancer patients. Breast Cancer Res Treat 2001; 66: 255-63
31. Jurisic V, Srdic T, Konjevic G, et al. Clinical stage-depending decrease of NK cell activity in multiple myeloma patients. Med Oncol 2007; 24: 312-17
32. Lagrue K, Carisey A, Morgan DJ, et al. Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds. Blood 2015; 126: 50-60
33. Jurisic V, Srdic-Rajic T, Konjevic G, et al. TNF-A induced apoptosis is accompanied with rapid CD30 and slower CD45 shedding from K-562 cells. J Membr Biol 2011; 239: 115-22
34. KonjevićG, SpuzićI. Evaluation of different effects of sera of breast cancer patients on the activity of natural killer cells. J Clin Lab Immunol 1992; 38: 83-93
35. Azzoni L, Zatsepina O, Abebe B, et al. Differential transcriptional regulation of CD161 and a novel gene, 197/15a, by IL-2, IL-15, and IL-12 in NK and T cells. J Immunol 1998; 161: 3493-500
36. Rosen DB, Bettadapura J, Alsharifi M, et al. Cutting edge: lectin-like transcript-1 is a ligand for the inhibitory human NKR-P1A receptor. J Immunol 2005; 175: 7796-9
37. Aldemir H, Prod'homme V, Dumaurier MJ, et al. Cutting edge: lectinlike transcript 1 is a ligand for the CD161 receptor. J Immunol 2005; 175: 7791-5
38. KonjevićG, Mirjaç.ićMartinovićK, VuletićA, et al. Novel aspects of in vitro IL-2 or IFN-A enhanced NK cytotoxicity of healthy individuals based on NKG2D and CD161 NK cell receptor induction. Biomed Pharmacother 2010; 64: 663-71
39. KonjevićG, Mirjaç.ićMartinovićK, VuletićA, et al. In-vitro IL-2 or IFN-A-induced NKG2D and CD161 NK cell receptor expression indicates novel aspects of NK cell activation in metastatic melanoma patients. Melanoma Res 2010; 20: 459-67
40. Mirjaç.ićMartinovićK, BabovićN, DžodićR, et al. Favorable in vitro effects of combined IL-12 and IL-18 treatment on NK cell cytotoxicity and CD25 receptor expression in metastatic melanoma patients. J Transl Med 2015; 13: 120
41. VuletićAM, JovanićIP, JurišićVB, et al. In-vitro activation of natural killer cells from regional lymph nodes of melanoma patients with interleukin-2 and interleukin-15. Melanoma Res 2015; 25: 22-34
42. Parham P. Immunogenetics of killer cell immunoglobulinlike receptors. Mol Immunol 2005; 42: 459-62
43. KonjevićG, Mirjaç.ić-MartinovićK, JurišićV, et al. Biomarkers of suppressed natural killer (NK) cell function in metastatic melanoma: Decreased NKG2D and increased CD158a receptors on CD3-CD16+ NK cells. Biomarkers 2009; 14: 258-70
44. Pan XH, Guo KY, Song JG, et al. Modulation of the rate of CD158a+/b+ cells by Th1-And Th2-like cytokines]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2003; 19: 56-8
45. Zhang C, Zhang J, Wei H, et al. Imbalance of NKG2D and its inhibitory counterparts: how does tumor escape from innate immunity?. Int Immunopharmacol 2005; 5: 1099-111
46. Korde N, Carlsten M, Lee MJ, et al. A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma. Haematologica 2014; 99: e81-3
47. Thielens A, Vivier E, Romagné F. NK cell MHC class I specific receptors (KIR): from biology to clinical intervention. Curr Opin Immunol 2012; 24: 239-45
48. Kröger N, Shaw B, Iacobelli S, et al, Clinical Trial Committee of the British Society of Blood and Marrow Transplantation and the German Cooperative Transplant Group. Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. Br J Haematol 2005; 129: 631-43
49. Pico De Coaña Y, Choudhury A, et al. Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system. Trends Mol Med 2015; 21: 482-91
50. Cook G, Campbell JD, Carr CE, et al. Transforming growth factor beta from multiple myeloma cells inhibits proliferation and IL-2 responsiveness in T lymphocytes. J Leukoc Biol 1999; 66: 981-8
51. Campbell JD, Cook G, Robertson SE, et al. Suppression of IL-2-induced T cell proliferation and phosphorylation of STAT3 and STAT5 by tumor-derived TGF beta is reversed by IL-15. J Immunol 2001; 167: 553-61
52. Filella X, Bladé J, Montoto S, et al. Impaired production of interleukin 6 and tumour necrosis factor alpha in whole blood cell cultures of patients with multiple myeloma. Cytokine 1998; 10: 993-6
53. Duan LJ, Li C, Yang RY. [Values of Detecting the Levels of β2-MG, TNF-A, CRP, IL-6 in the Patients with Multiple Myeloma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2015; 23: 1362-5
54. Pratt G, Goodyear O, Moss P. Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol 2007; 138: 563-79
55. Vitale M, Cantoni C, Pietra G, et al. Effect of tumor cells and tumor microenvironment on NK-cell function. Eur J Immunol 2014; 44: 1582-92
56. Wang D, DuBois RN. Immunosuppression associated with chronic inflammation in the tumor microenvironment. Carcinogenesis 2015; 36: 1085-93